Author： Gerber Andreas
Publisher： Adis International
ISSN： 1170-7690
Source： PharmacoEconomics, Vol.29, Iss.7, 2011-07, pp. : 549-553
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Bortezomib: one step closer to value-based pricing?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 533, 2007-01 ,pp. :
Access to resources
Recommend
Value-Based Pricing: Incentive for Innovation or Zero Net Benefit?
PharmacoEconomics, Vol. 29, Iss. 9, 2011-09 ,pp. :
Are Irish eyes smiling on generic substitution, reference pricing?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 607, 2010-01 ,pp. :
Value-based pricing hot at ISPOR
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 642, 2011-01 ,pp. :
Reference pricing or HTA for obtaining best value from drugs?
PharmacoEconomics and Outcomes News, Vol. 1, Iss. 540, 2007-01 ,pp. :